<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447718</url>
  </required_header>
  <id_info>
    <org_study_id>SI02</org_study_id>
    <nct_id>NCT02447718</nct_id>
  </id_info>
  <brief_title>Vaccinating Children After Chemotherapy</brief_title>
  <official_title>Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Immunization Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Immunization Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center open label clinical trial aims to identify predictors of low antibody&#xD;
      titers to vaccine antigens in children with ALL who completed chemotherapy in the prior 6&#xD;
      months, and to determine the immunogenicity and safety of diphtheria-tetanus-acellular&#xD;
      pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-Hib) and&#xD;
      13-valent pneumococcal conjugate vaccine (PCV13) booster immunization administered 6 months&#xD;
      post-chemotherapy, followed by 23-valent pneumococcal polysaccharide vaccination (PPV23) 2&#xD;
      months later. The results will support the development of clinical practice guidelines for&#xD;
      this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and Aims: Children with acute lymphoblastic leukemia (ALL) have evidence of&#xD;
      persistent immunosuppression following chemotherapy and may experience waning of immunity to&#xD;
      vaccines received prior to treatment. There is no standard of care in Canada regarding&#xD;
      immunologic evaluation or booster immunization of children with ALL after chemotherapy. This&#xD;
      study aims to identify predictors of low baseline immunity to vaccine antigens in children&#xD;
      with ALL and to evaluate the immunogenicity and safety of a standard immunization regimen:&#xD;
      DTaP-IPV-Hib and PCV13 booster immunization administered 6 months post-chemotherapy, followed&#xD;
      by PPV23.&#xD;
&#xD;
      Study Design: This will be a multi-center open-label clinical trial in which children who&#xD;
      were diagnosed with ALL at ≥1 year of age, and have not received immunizations other than&#xD;
      influenza since completing chemotherapy will undergo immunologic evaluation and serologic&#xD;
      testing for pneumococcus, tetanus, pertussis and varicella. They will then be immunized with&#xD;
      PCV13, DTaP-IPV-Hib, regardless of immunization history [unless PPV23 was received within the&#xD;
      prior 12 months]. Other routine vaccines required as per provincial and centre-specific&#xD;
      immunization policies will also be administered. PPV23 will be administered 8 weeks after&#xD;
      PCV13. Repeat serologic testing will be conducted at 2 months and 12-15 months after&#xD;
      DTaP-IPV-Hib and PCV13 immunization to assess short and long-term immune responses.&#xD;
&#xD;
      Adverse events following immunization (AEFI) will be captured through standardized telephone&#xD;
      interviews on days 8-10 and 30-33 post-immunization that will capture local and systemic&#xD;
      AEFI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Actual">March 5, 2018</completion_date>
  <primary_completion_date type="Actual">March 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23</measure>
    <time_frame>Pre-vaccination Baseline, 2 months and 12-15 months</time_frame>
    <description>The percentage of participants with protective titres (with protective level defined as ≥0.35 ug/ml, as per World Health Organization criteria) to PCV13 serotypes will be assessed at 2 months and 12-15 months post PCV13+PPV23 and compared to baseline levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protective Titres to PCV7 Serotypes at Baseline</measure>
    <time_frame>Day 0</time_frame>
    <description>The number of participants with protective titres (≥0.35 ug/ml) to PCV7 serotypes at baseline will be compared to age-matched controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Pneumococcal Antibody Titres in Subjects With ALL Versus Controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Baseline geometric mean titers (GMT) and percentage of subjects with protective titres to pneumococcal serotypes in children with ALL versus age-matched controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Responses to Pertussis Toxin Following DTaP-IPV-Hib Booster Vaccination</measure>
    <time_frame>Prevaccination baseline, 2 months, 12-15 months</time_frame>
    <description>Baseline, Short-term (baseline - 2 months after vaccination) and long-term (baseline - 12-15 months) vaccine responses to DTaP-IPV-Hib will be measured using GMT ratios.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Tetanus Toxoid Antibody Titers in Children With ALL Versus Controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Baseline geometric mean titers (95% confidence intervals) reported as IU/ml in children with ALL versus controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Pertussis Toxin Titers in Children With ALL Versus Healthy Controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Baseline geometric mean titers (95% confidence intervals) reported as IU/ml in children with ALL versus controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Varicella Titers in Children With ALL Versus Controls.</measure>
    <time_frame>Day 0</time_frame>
    <description>Geometric mean titers (95% confidence interval) in AI (antibody index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Responses to Tetanus Toxoid Following DTaP-IPV-Hib Immunization</measure>
    <time_frame>baseline, 2 months, 12-15 months</time_frame>
    <description>Baseline, short-term (baseline to 2 months after vaccination) and long-term (baseline to 12-15 months) vaccine responses to DTaP-IPV-Hib will be measured using GMTs with 95% confidence intervals</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Events Following Immunization Requiring Healthcare Visit or Leading to &gt;=1 Day of Disability</measure>
    <time_frame>days 8-10 and 30-33</time_frame>
    <description>Adverse Events Following Immunization requiring healthcare visit or leading to &gt;=1 day of disability will be captured through structured telephone interviews on days 8-10 and 30-33 after each immunization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar®13</intervention_name>
    <description>A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>13- valent conjugate pneumococcal vaccine</other_name>
    <other_name>PCV13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax® 23</intervention_name>
    <description>A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>23-valent polysaccharide pneumococcal vaccine</other_name>
    <other_name>PPV23</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediacel®</intervention_name>
    <description>A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>DTaP-IPV-Hib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cases with ALL:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with standard, high-risk or very-high risk ALL&#xD;
&#xD;
          -  Age at diagnosis: ≥1 year of age (age at enrollment: ≥3 years)&#xD;
&#xD;
          -  Completed chemotherapy 3 to 12 months prior to enrollment&#xD;
&#xD;
          -  No evidence of ALL relapse or secondary malignancy&#xD;
&#xD;
          -  No known primary immunodeficiency&#xD;
&#xD;
          -  No receipt of pneumococcal or tetanus-containing vaccines since completing&#xD;
             chemotherapy&#xD;
&#xD;
          -  No history of allergy to any component of PCV13&#xD;
&#xD;
          -  Caregiver and/or participant is English or French-speaking and able to provide written&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infantile ALL&#xD;
&#xD;
          -  Evidence of disease relapse or secondary malignancy&#xD;
&#xD;
          -  History of underlying primary immunodeficiency&#xD;
&#xD;
          -  Transplant recipient&#xD;
&#xD;
          -  Received intravenous immunoglobulin (IVIG) within past 9 months or other blood&#xD;
             products within the prior 3 months.Children who received PPV23 within 12 months of&#xD;
             enrollment will not be eligible to receive PCV13 or PPV23. These children can still&#xD;
             participate in the baseline evaluation, receive DTaP-Hib-IPV vaccine, and have tetanus&#xD;
             and pertussis serology measured at 2 and 12-15 months post-immunization.&#xD;
&#xD;
        Controls:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Children 3-18 years of age, age-matched to cases&#xD;
&#xD;
          -  Caregiver and/or participant is English or French-speaking and able to provide written&#xD;
             informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  History of primary or secondary immunodeficiency including aplastic anemia,&#xD;
             malignancy, nephrotic syndrome, malabsorption or severe malnutrition&#xD;
&#xD;
          -  Immunosuppressive therapy within 3 months of enrollment (excluding inhaled&#xD;
             corticosteroids)&#xD;
&#xD;
          -  Received intravenous immunoglobulin (IVIG) within past 9 months or other blood&#xD;
             products within the prior 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karina Top, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Canadian Immunization Research Network</investigator_affiliation>
    <investigator_full_name>Karina Top</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02447718/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited based on physician referral across 10 pediatric centres. Controls were recruited at 3 centres. Participants were enrolled between November 2015 to September 2017.</recruitment_details>
      <pre_assignment_details>155 of the 156 participants recruited met inclusion criteria. Of the 78 participants with ALL recruited, 1 did not meet inclusion criteria and 3 withdrew consent prior to study start. All of the 78 control participants met inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Control</title>
          <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Prevnar®13</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="0">Do not receive vaccination</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Pediacel®</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="0">Do not receive vaccination</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Pneumovax® 23</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="0">Do not receive vaccination</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Control</title>
          <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" lower_limit="3.8" upper_limit="19.3"/>
                    <measurement group_id="B2" value="8.3" lower_limit="3.5" upper_limit="18.9"/>
                    <measurement group_id="B3" value="8.2" lower_limit="3.5" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALL disease risk category</title>
          <description>Disease risk category based on patient characteristics at leukemia diagnosis reflects intensity of chemotherapy</description>
          <population>Only collected for ALL participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Standard risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Protocol</title>
          <population>Only collected for ALL participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Children's Oncology Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dana Farber Cancer Institute</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interval from last chemotherapy to serology</title>
          <description>Time in months between last chemotherapy session to baseline blood draw.</description>
          <population>Only collected for ALL participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="B3" value="6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total white blood cell count at enrollment</title>
          <description>Only available for participants with analyzable data</description>
          <population>Only collected for participants with AL. Immunological markers not available on all participants with ALL, denominator reflects number of participants with analyzable values for each test.</population>
          <units>cells x10^9/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="5.3" upper_limit="7.7"/>
                    <measurement group_id="B3" value="6.5" lower_limit="5.3" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total lymphocyte count at enrollment</title>
          <description>Only available for participants with analyzable data</description>
          <population>Only collected for participants with ALL. Immunological markers not available on all participants with ALL, denominator reflects number of participants with analyzable values for each test.</population>
          <units>cells x10^9/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="1.7" upper_limit="2.9"/>
                    <measurement group_id="B3" value="2.3" lower_limit="1.7" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymphocyte subsets at enrollment</title>
          <population>Only collected for participants with ALL. Immunological markers not available on all participants with ALL, denominator reflects number of participants with analyzable values for each test.</population>
          <units>cells x10^9/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>CD3+ T cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="1.1" upper_limit="1.9"/>
                    <measurement group_id="B3" value="1.4" lower_limit="1.1" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ T cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" lower_limit="0.6" upper_limit="1.0"/>
                    <measurement group_id="B3" value="0.8" lower_limit="0.6" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ T cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NK cells (CD56+/CD16+)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.2" lower_limit="0.1" upper_limit="0.2"/>
                    <measurement group_id="B3" value="0.2" lower_limit="0.1" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19+ B cells</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.6" lower_limit="0.4" upper_limit="0.7"/>
                    <measurement group_id="B3" value="0.6" lower_limit="0.4" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total serum IgG at enrollment</title>
          <description>Only available for participants with analyzable data</description>
          <population>Only collected for participants with ALL. Immunological markers not available on all participants with ALL, denominator reflects number of participants with analyzable values for each test.</population>
          <units>g/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="71"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" lower_limit="7.1" upper_limit="11.1"/>
                    <measurement group_id="B3" value="8.5" lower_limit="7.1" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous doses of PCV</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received more than ≥1 dose at ≥12 months of age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received more than ≥1 dose PCV13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous doses of DTaP or Tdap</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous doses of varicella vaccine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interval from last vaccine to baseline blood draw</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>DTaP/Tdap-containing vaccine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread="2.7"/>
                    <measurement group_id="B2" value="3.7" spread="2.5"/>
                    <measurement group_id="B3" value="4.85" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="2.3"/>
                    <measurement group_id="B2" value="7.2" spread="3.4"/>
                    <measurement group_id="B3" value="6.3" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="78"/>
                    <count group_id="B3" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="3.2"/>
                    <measurement group_id="B2" value="5.2" spread="4.2"/>
                    <measurement group_id="B3" value="5.85" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23</title>
        <description>The percentage of participants with protective titres (with protective level defined as ≥0.35 ug/ml, as per World Health Organization criteria) to PCV13 serotypes will be assessed at 2 months and 12-15 months post PCV13+PPV23 and compared to baseline levels.</description>
        <time_frame>Pre-vaccination Baseline, 2 months and 12-15 months</time_frame>
        <population>Participants analyzed equaled the overall number of ALL participants that completed the study and had analyzable serology collected at 2 months and 12-15 months post-vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23</title>
          <description>The percentage of participants with protective titres (with protective level defined as ≥0.35 ug/ml, as per World Health Organization criteria) to PCV13 serotypes will be assessed at 2 months and 12-15 months post PCV13+PPV23 and compared to baseline levels.</description>
          <population>Participants analyzed equaled the overall number of ALL participants that completed the study and had analyzable serology collected at 2 months and 12-15 months post-vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 months post-PCV13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-15 months post-PCV13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protective Titres to PCV7 Serotypes at Baseline</title>
        <description>The number of participants with protective titres (≥0.35 ug/ml) to PCV7 serotypes at baseline will be compared to age-matched controls.</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protective Titres to PCV7 Serotypes at Baseline</title>
          <description>The number of participants with protective titres (≥0.35 ug/ml) to PCV7 serotypes at baseline will be compared to age-matched controls.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Pneumococcal Antibody Titres in Subjects With ALL Versus Controls</title>
        <description>Baseline geometric mean titers (GMT) and percentage of subjects with protective titres to pneumococcal serotypes in children with ALL versus age-matched controls.</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pneumococcal Antibody Titres in Subjects With ALL Versus Controls</title>
          <description>Baseline geometric mean titers (GMT) and percentage of subjects with protective titres to pneumococcal serotypes in children with ALL versus age-matched controls.</description>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumococcal Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.16" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.41" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.72" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.16" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.43" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.29" upper_limit="0.50"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.92" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.20" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.57" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.37" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.92" lower_limit="0.77" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.35" upper_limit="0.59"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1.24" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.16" upper_limit="0.27"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.38" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.77" upper_limit="1.26"/>
                    <measurement group_id="O2" value="3.21" lower_limit="2.73" upper_limit="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumococcal Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.23" upper_limit="0.36"/>
                    <measurement group_id="O2" value="1.15" lower_limit="0.87" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Responses to Pertussis Toxin Following DTaP-IPV-Hib Booster Vaccination</title>
        <description>Baseline, Short-term (baseline - 2 months after vaccination) and long-term (baseline - 12-15 months) vaccine responses to DTaP-IPV-Hib will be measured using GMT ratios.</description>
        <time_frame>Prevaccination baseline, 2 months, 12-15 months</time_frame>
        <population>A total of 73 participants received DTaP-IPV-Hib, 67 provided a follow up sample at 2 months post-vaccination and 66 provided a follow up sample at 12 months post-vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13 Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Responses to Pertussis Toxin Following DTaP-IPV-Hib Booster Vaccination</title>
          <description>Baseline, Short-term (baseline - 2 months after vaccination) and long-term (baseline - 12-15 months) vaccine responses to DTaP-IPV-Hib will be measured using GMT ratios.</description>
          <population>A total of 73 participants received DTaP-IPV-Hib, 67 provided a follow up sample at 2 months post-vaccination and 66 provided a follow up sample at 12 months post-vaccination.</population>
          <units>EU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-vaccination Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" lower_limit="3.67" upper_limit="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - 2 months post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.67" lower_limit="22.25" upper_limit="42.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - 12-15 months post-vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.39" lower_limit="7.76" upper_limit="13.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Tetanus Toxoid Antibody Titers in Children With ALL Versus Controls</title>
        <description>Baseline geometric mean titers (95% confidence intervals) reported as IU/ml in children with ALL versus controls</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Tetanus Toxoid Antibody Titers in Children With ALL Versus Controls</title>
          <description>Baseline geometric mean titers (95% confidence intervals) reported as IU/ml in children with ALL versus controls</description>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.12" upper_limit="0.20"/>
                    <measurement group_id="O2" value="1.73" lower_limit="1.26" upper_limit="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Pertussis Toxin Titers in Children With ALL Versus Healthy Controls</title>
        <description>Baseline geometric mean titers (95% confidence intervals) reported as IU/ml in children with ALL versus controls</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pertussis Toxin Titers in Children With ALL Versus Healthy Controls</title>
          <description>Baseline geometric mean titers (95% confidence intervals) reported as IU/ml in children with ALL versus controls</description>
          <units>EU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" lower_limit="3.67" upper_limit="4.58"/>
                    <measurement group_id="O2" value="10.35" lower_limit="8.15" upper_limit="13.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Varicella Titers in Children With ALL Versus Controls.</title>
        <description>Geometric mean titers (95% confidence interval) in AI (antibody index)</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Varicella Titers in Children With ALL Versus Controls.</title>
          <description>Geometric mean titers (95% confidence interval) in AI (antibody index)</description>
          <units>Antibody index</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.24" upper_limit="0.45"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.77" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Responses to Tetanus Toxoid Following DTaP-IPV-Hib Immunization</title>
        <description>Baseline, short-term (baseline to 2 months after vaccination) and long-term (baseline to 12-15 months) vaccine responses to DTaP-IPV-Hib will be measured using GMTs with 95% confidence intervals</description>
        <time_frame>baseline, 2 months, 12-15 months</time_frame>
        <population>Participants with analyzable data at each timepoint were included</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13 Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Responses to Tetanus Toxoid Following DTaP-IPV-Hib Immunization</title>
          <description>Baseline, short-term (baseline to 2 months after vaccination) and long-term (baseline to 12-15 months) vaccine responses to DTaP-IPV-Hib will be measured using GMTs with 95% confidence intervals</description>
          <population>Participants with analyzable data at each timepoint were included</population>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-vaccination Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.12" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - 2 months post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.57" upper_limit="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - 12-15 months post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.77" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events Following Immunization Requiring Healthcare Visit or Leading to &gt;=1 Day of Disability</title>
        <description>Adverse Events Following Immunization requiring healthcare visit or leading to &gt;=1 day of disability will be captured through structured telephone interviews on days 8-10 and 30-33 after each immunization</description>
        <time_frame>days 8-10 and 30-33</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.&#xD;
Prevnar®13: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.&#xD;
Pneumovax® 23: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13&#xD;
Pediacel®: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Following Immunization Requiring Healthcare Visit or Leading to &gt;=1 Day of Disability</title>
          <description>Adverse Events Following Immunization requiring healthcare visit or leading to &gt;=1 day of disability will be captured through structured telephone interviews on days 8-10 and 30-33 after each immunization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Possibly related to vaccination</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unrelated to vaccination</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No AEFI requiring healthcare visit or leading to &gt;=1 day of disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEFI was captured through structured telephone interviews on days 8-10 and 30-33 after each immunization</time_frame>
      <desc>Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Adverse Events were not monitored for Healthy Controls as they did not receive the interventions, they provided baseline data only.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTaP-IPV-HiB+PCV13</title>
          <description>DTaP-IPV-Hib: diphtheria-tetanus-acellular pertussis-inactivated polio-H. influenzae type b vaccine&#xD;
PCV13: 13-valent pneumococcal conjugate vaccine</description>
        </group>
        <group group_id="E2">
          <title>PPV23</title>
          <description>PPV23: 23-valent pneumococcal polysaccharide vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic symptoms</sub_title>
                <description>Systemic symptoms included fever, malaise, gastrointestinal symptoms, skin rash, headache, pharyngitis, otitis media</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/erythema/swelling at injection site</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Antibody levels to vaccine antigens were not measured before chemotherapy, cannot confirm that chemotherapy was the cause of low postchemotherapy titers.&#xD;
Immunization status at ALL diagnosis was not assessed and therefore could not confirm whether postchemotherapy participants were underimmunized for age before diagnosis relative to their peers.&#xD;
We were unable to assess antibodies to other pertussis antigens (eg, filamentous hemagglutinin, pertactin), only anti-PT antibodies alone.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Karina Top</name_or_title>
      <organization>IWK Health Centre</organization>
      <phone>902-470-6343</phone>
      <email>karina.top@dal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

